High ceftaroline non-susceptibility in Staphylococcus aureus isolated from acute skin infections in 15 tertiary hospitals in China

References

1. CLSI 2009; Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 8th edn; Approved Standard. M7-A8. Wayne, PA: Clinical and Laboratory Standards Institute;
2. CLSI 2012; Performance Standards for Antimicrobial Susceptibility Testing; 22nd Informational Supplement. M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute;
3. Jones R. N., Mendes R. E., Sader H. S. 2010; Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 65:Suppl. 4iv17–iv31 [CrossRef][PubMed]
   [Google Scholar]
4. Richter S. S., Heilmann K. P., Dohrn C. L., Riahi F., Costello A. J., Kroeger J. S., Biek D., Critchley I. A., Diekema D. J., Doern G. V. 2011; Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother 55:4154–4160 [CrossRef][PubMed]
   [Google Scholar]
5. Saravolatz L. D., Stein G. E., Johnson L. B. 2011; Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 52:1156–1163 [CrossRef][PubMed]
   [Google Scholar]